AI assistant
Lupin Ltd — Capital/Financing Update 2020
May 19, 2020
61031_rns_2020-05-19_e5a74179-aa68-4ba4-820c-1c76a0a5729d.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [84 x 99] intentionally omitted <==
May 19, 2020
BSE Limited,
Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex, Bandra (East), MUMBAI - 400 051.
Dear Sir/Madam,
Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Enclosed is a Press Release as regards launch of authorized generic version of Bausch Health’s Apriso[®] (Mesalamine Extended-Release Capsules 0.375 g) by the Company in the U.S.
This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
For LUPIN LIMITED
Digitally signed by RAJVARDHAN VISHNU SATAM RAJVARDH DN: c=IN, o=Personal, postalCode=400062, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d 3924b2532eb2f496ea7e2abcf74700f537 AN VISHNU 5b7, serialNumber=df8ebe60a88c796663c738 ea25bfa0b475d195f726cdb67a2ff09c424 SATAM 2771b2a, cn=RAJVARDHAN VISHNU SATAM Date: 2020.05.19 11:11:27 +05'30'
R. V. SATAM COMPANY SECRETARY (ACS - 11973)
Encl- : a/a.
Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com
Press Release
==> picture [68 x 70] intentionally omitted <==
BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN
Lupin Launches Authorized Generic Version of Apriso®
Mumbai, Baltimore, May 19, 2020 : Pharma major Lupin Limited (Lupin) announced the launch of authorized generic version of Bausch Health’s Apriso® (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.
Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso® had an annual sales of approximately USD 290 million in the U.S. (IQVIA MAT March 2020).
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information. Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/ Facebook: www.facebook.com/LupinWorld/
For further information or queries please contact –
| further information orqueriesplease contact – | |
|---|---|
| Arvind Bothra | Manjira Sharma |
| Head – Investor Relations and Corporate Communications | General Manager – Corporate Communications |
| Email:[email protected] | Email:[email protected] |
| Tel: +91 22 6640 8237 | Tel: +91 22 6640 2532 |
*Safe Harbor Statement
Apriso® is a registered trademark of Bausch Health Companies Inc.
Page 1 of 1